Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 951A, 250, 163(j), 168, 55, 56A, 59, 174 and 41. (H.R. 2673, H.R. 7024).
Duration: January 12, 2016
to
present
General Issues: Taxation/Internal Revenue Code
Spending: about $5,930,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Treasury - Dept of, Natl Economic Council (NEC), Office of Management & Budget (OMB)
Affiliated organizations: AbbVie Inc.; Amgen Inc.; Baxalta Inc.; Celgene Corporation; Eli Lilly Company; Gilead; Johnson & Johnson Services Inc.; Merck & Co., Inc.
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Greg Nickerson Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Subcommittee
Jan Fowler Leg. Asst, Senator Voinovich; Leg. Asst., Leg. Correspondent, Staff Asst., Intern Rep. McCrery
Leg. Asst, Sen. Voinovich; Leg. Assistant, Leg. Correspondent, Staff Assistant, Intern from Rep. McCrery
Brian Diffell Policy Advisor, Senate Rep. Conference; Leg. Dir. Sen. Blunt; Leg. Director Rep. Blunt; Sr. Policy Adv. Rep. Majority Whip; Sr. Policy Adv. House Majority Whip; Research Analyst, House Maj. Whip; Spec. Asst. to the Chief Deputy Whip
Policy Adv., Sen. Rep. Conference: Leg. Director Sen. Blunt; Leg. Dir. Rep. Blunt; Sr. Policy Adv. Rep. Maj. Whip; Sr. Policy Adv. House Maj. Whip; Research Analyst, House Maj. Whip; Spec. Asst to the Chief Deputy Whip Blunt
Kelli Briggs oChief of Staff, 12th Congressional District of Ohio; Chief of Staff, D.C. Chief of Staff, Deputy Chief of Staff, Legislative Director, Legislative Assistant, Legislative Correspondent, Staff Assistant, Intern from Rep. Tiberi
oChief of Staff, 12th Congressional District of Ohio; Chief of Staff, D.C. Chief of Staff, Deputy Chief of Staff, Legislative Director, Legislative Assistant, Legislative Correspondent, Staff Assistant, Intern for Rep. Tiberi
Zach Price n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE WASHINGTON TAX & PUBLIC POLICY GROUP lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $460,000. The report was filed on April 18.
Original Filing: 301554129.xml
Lobbying Issues
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 951A, 250, 163(j), 168, 55, 56A, 59, 174 and 41. (H.R. 2673, H.R. 7024).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $50,000. The report was filed on Jan. 11.
Original Filing: 301523528.xml
Lobbying Issues
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 951A, 250, 163(j), 168, 55, 56A, 59, 174 and 41. (H.R. 2673, H.R. 3938, Treas. Notice 2023-64). Issues related to foreign tax credits. (T.D. 9959)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $480,000. The report was filed on Oct. 17, 2023.
Original Filing: 301503119.xml
Lobbying Issues
Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 951A, 250, 163(j), 168, 55, 56A, 59, 174 and 41. (H.R. 2673, H.R. 3938, Treas. Notice 2023-64). Issues related to foreign tax credits. (T.D. 9959)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $70,000. The report was filed on July 20, 2023.
Original Filing: 301488572.xml
Lobbying Issues
Issues related to corporate and international taxation and issues related to OECD negotiations on the taxation of global income. Issues related to tax code sections 951A, 250, 163(j), 168, 55, 56A, 174 and 41. (H.R. 2673 and H.R. 3938). Issues related to foreign tax credits. (T.D. 9959; H.R. 4029). Issues related to the Chilean Tax Treaty. (Treaty Document 112-8)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $410,000. The report was filed on April 19, 2023.
Original Filing: 301458154.xml
Lobbying Issues
Issues related to corporate and international taxation and issues related to OECD negotiations on the taxation of global income, including tax code sections 951A, 250, 163(j), 55, 56A, and 41. Issues related to the amortization of research and experimentation expenses, including tax code section 174. Issues related to foreign tax credits, including T.D. 9959.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $40,000. The report was filed on Jan. 19, 2023.
Original Filing: 301434294.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to tax code sections 951A, 250, 245A, 163, 59A, 55 and 56A. Issues related to the amortization of research and experimentation expenses, H.R. 1304 and tax code section 174. Issues related to OECD negotiations on the taxation of global income. Issues related to foreign tax credits, including T.D. 9959.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $440,000. The report was filed on Oct. 13, 2022.
Original Filing: 301403743.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, 245A, 163, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico. Issues related to the amortization of research and experimentation expenses, H.R. 1304. Issues related to OECD negotiations on the taxation of global income. Issues related to H.R.5376 - Build Back Better Act, including sections 138101, 138111, 138121, 138124, 138126, 138127, 138128, 138131, and 138516. Issues related to foreign tax credits, including T.D. 9959. Issues related to H.R.5376 - Inflation Reduction Act, including section 10101.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301392714.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, 245A, 163, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico. Issues related to the amortization of research and experimentation expenses, H.R. 1304. Issues related to OECD negotiations on the taxation of global income. Issues related to H.R.5376 - Build Back Better Act, including sections 138101, 138111, 138121, 138124, 138126, 138127, 138128, 138131, and 138516. Issues related to foreign tax credits, including T.D. 9959.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $440,000. The report was filed on April 18, 2022.
Original Filing: 301359291.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, 245A, 163, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico. Issues related to the amortization of research and experimentation expenses, H.R. 1304. Issues related to OECD negotiations on the taxation of global income. Issues related to H.R.5376 - Build Back Better Act, including sections 138101, 138111, 138121, 138124, 138126, 138127, 138128, 138131, and 138516. Issues related to foreign tax credits, including T.D. 9959.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325792.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, 245A, 163, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico. Issues related to the amortization of research and experimentation expenses, H.R. 1304. Issues related to OECD negotiations on the taxation of global income. Issues related to H.R.5376 - Build Back Better Act, including sections 138101, 138111, 138121, 138124, 138126, 138127, 138128, 138131, and 138516.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $360,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313120.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, 245A and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico. Issues related to the amortization of research and experimentation expenses, H.R. 1304. Issues related to OECD negotiations on the taxation of global income. Issues related to H.R.5376 - Build Back Better Act, including sections 138101, 138111, 138121, 138124, 138126, 138127, 138128, 138131, and 138516.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $50,000. The report was filed on July 19, 2021.
Original Filing: 301281889.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico, and issues related to the repatriation of intellectual property. Issues related to the amortization of research and experimentation expenses. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $360,000. The report was filed on April 20, 2021.
Original Filing: 301264182.xml
Lobbying Issues
Issues related to corporate and international taxation, including issues related to corporate tax rates, issues related to the taxation of foreign income, including tax code sections 951A, 250, and 59A. Issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico, and issues related to the repatriation of intellectual property. Issues related to the amortization of research and experimentation expenses. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240189.xml
Lobbying Issues
Issues related to corporate and international tax, including issues related to corporate tax rates, issues related to the taxation of foreign income, tax code sections 951A and 954(c)(6), issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico, and issues related to the repatriation of intellectual property (H.R. 7749). Issues related to the creditability of Puerto Rico excise taxes. (IRS REG-101657-20 - Guidance Related to the Foreign Tax Credit; Clarification of Foreign-Derived Intangible Income). Issues related to the amortization of research and experimentation expenses. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2020
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $270,000. The report was filed on Oct. 15, 2020.
Original Filing: 301210211.xml
Lobbying Issues
Issues related to corporate and international tax, including issues related to rates, tax code section 951A, issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico, and issues related to the repatriation of intellectual property (H.R. 7749). Issues related to the creditability of Puerto Rico excise taxes. Informational inquiry into the operation of the payroll tax deferral memorandum. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2020
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301197040.xml
Lobbying Issues
Issues related to corporate and international tax, including issues related to the taxation of manufacturing income and capital investment in the United States and Puerto Rico and issues related to the repatriation of intellectual property. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2020
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $240,000. The report was filed on April 17, 2020.
Original Filing: 301169362.xml
Lobbying Issues
Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), and 174. Issues rated to U.S. manufacturing investment and intellectual property and issues related to Puerto Rico incentives and excise taxes. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2019
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on Jan. 17, 2020.
Original Filing: 301108817.xml
Lobbying Issues
Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, and 174. Issues related to Puerto Rico incentives and excise taxes. Issues related to OECD negotiations on the taxation of global income. The Further Consolidated Appropriations Act, 2020, H.R. 1865.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $240,000. The report was filed on Oct. 17, 2019.
Original Filing: 301067640.xml
Lobbying Issues
Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, and 174. Issues related to Puerto Rico incentives and excise taxes. Issues related to Tax Treaties. Issues related to OECD negotiations on the taxation of global income.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on July 11, 2019.
Original Filing: 301044423.xml
Lobbying Issues
Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, and 174. Issues related to Puerto Rico incentives and excise taxes. Tax Treaties and digital services taxation.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $210,000. The report was filed on April 9, 2019.
Original Filing: 301023457.xml
Lobbying Issues
Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentives and excise taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $60,000. The report was filed on Jan. 17, 2019.
Original Filing: 301006813.xml
Lobbying Issues
Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentives and excise taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $210,000. The report was filed on Oct. 15, 2018.
Original Filing: 300985444.xml
Lobbying Issues
Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentives and excise taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300970514.xml
Lobbying Issues
Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $270,000. The report was filed on April 19, 2018.
Original Filing: 300949593.xml
Lobbying Issues
Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $110,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934767.xml
Lobbying Issues
Issues related to corporate and international tax reform including corporate tax rate, interest deductibility, IRC section 965, anti-base erosion provisions, foreign derived intangible income, tax treatment of U.S sales, and global intangible low-taxed income.(HR 1).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $200,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904457.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $50,000. The report was filed on July 18, 2017.
Original Filing: 300886609.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $170,000. The report was filed on April 13, 2017.
Original Filing: 300865137.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $60,000. The report was filed on Jan. 19, 2017.
Original Filing: 300850073.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $210,000. The report was filed on Oct. 14, 2016.
Original Filing: 300827801.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system. Issues related to proposed Treasury IRC 385 regulations.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
The Washington Tax & Public Policy Group (formerly The Washington Tax Group) amended a lobbying report for representation of Alliance for Biopharmaceutical Competitiveness and Innovation in Q22016 on July 12, 2016.
Original Filing: 300808342.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system. Issues related to proposed Treasury IRC 385 regulations.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $30,000. The report was filed on July 8, 2016.
Original Filing: 300807474.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
The Washington Tax & Public Policy Group (formerly The Washington Tax Group) amended a lobbying report for representation of Alliance for Biopharmaceutical Competitiveness and Innovation in Q12016 on April 19, 2016.
Original Filing: 300795675.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, The Washington Tax & Public Policy Group (formerly The Washington Tax Group) lobbied for Alliance for Biopharmaceutical Competitiveness and Innovation , earning $200,000. The report was filed on April 19, 2016.
Original Filing: 300794359.xml
Lobbying Issues
Issues related to international tax reform including transitioning to a territorial tax system.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
The Washington Tax & Public Policy Group (formerly The Washington Tax Group) filed a lobbying registration on Feb. 26, 2016 to represent Alliance for Biopharmaceutical Competitiveness and Innovation, effective Jan. 12, 2016.
Original Filing: 300787011.xml
Issue(s) they said they’d lobby about: Issues related to the taxation of the biopharmaceutical industry including international taxation .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...